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Background: There is a need for a survey instrument to measure arthralgia (joint pain) that has
been psychometrically validated in the context of existing reference instruments. We developed the
16-item Patient-Reported Arthralgia Inventory (PRAI) to measure arthralgia severity in 16 joints,
in the context of a longitudinal cohort study to assess aromatase inhibitor-associated arthralgia
in breast cancer survivors and arthralgia in postmenopausal women without breast cancer. We
sought to evaluate the reliability and validity of the PRAI instrument in these populations, as well
as to examine the relationship of patient-reported morning stiffness and arthralgia.
Methods: We administered the PRAI on paper in 294 women (94 initiating aromatase inhibitor therapy and 200 postmenopausal women without breast cancer) at weeks 0, 2, 4, 6, 8, 12,
16, and 52, as well as once in 36 women who had taken but were no longer taking aromatase
inhibitor therapy.
Results: Cronbach’s alpha was 0.9 for internal consistency of the PRAI. Intraclass correlation
coefficients of test-retest reliability were in the range of 0.87–0.96 over repeated PRAI administrations; arthralgia severity was higher in the non-cancer group at baseline than at subsequent
assessments. Women with joint comorbidities tended to have higher PRAI scores than those
without (estimated difference in mean scores: -0.3, 95% confidence interval [CI] -0.5, -0.2;
P0.001). The PRAI was highly correlated with the Functional Assessment of Cancer TherapyEndocrine Subscale item “I have pain in my joints” (reference instrument; Spearman r range:
0.76–0.82). Greater arthralgia severity on the PRAI was also related to decreased physical
function (r=-0.47, 95% CI -0.55, -0.37; P0.001), higher pain interference (r=0.65, 95% CI
0.57–0.72; P0.001), less active performance status (estimated difference in location (-0.6,
95% CI -0.9, -0.4; P0.001), and increased morning stiffness duration (r=0.62, 95% CI
0.54–0.69; P0.0001).
Conclusion: We conclude that the psychometric properties of the PRAI are satisfactory for
measuring arthralgia severity.
Keywords: arthralgia, joint pain, pain measurement, validation studies, questionnaire design,
aromatase inhibitors, postmenopause
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The Menopause Quality of Life/Breast Cancer Adjuvant Therapy longitudinal cohort
study was initiated in 2009 to investigate arthralgia (defined as inflammatory or
non-inflammatory joint pain) in postmenopausal women without breast cancer and
in women undergoing aromatase inhibitor (AI) therapy. Since 2006, AIs have been
the standard of care to prevent recurrence of hormone-sensitive early breast cancer in
postmenopausal women. Arthralgia occurs more frequently with age,1,2 and is a noted
secondary effect of AIs.3–6
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While several validated instruments exist to measure
arthritis (inflammatory joint pain),7–15 options for measuring arthralgia are limited. Because it may be non-inflammatory,
arthralgia might not manifest signs that are readily measurable
by a clinician. Hence, finding external and objective clinical
criteria to measure arthralgia effectively poses even more of
a challenge than it does for arthritis. Clinical arthritis assessments such as the Disease Activity Index for Rheumatoid
Arthritis16 are made up of subscales of tender and swollen
joint counts. Among rheumatoid arthritis patients, Pearson
correlation coefficients for clinician–patient agreement
on tender and swollen joint counts have been estimated in
meta-analysis to be 0.61 (tender) and 0.44 (swollen).17 Thus,
even with inflammatory joint pain, which has an externally
observable component, patients’ self-assessments are often
quite different from clinicians’ evaluations.
Magnetic resonance imaging may reveal disease processes of AI-associated arthralgia.18–20 However, as is often
the case with the measurement of pain, no simple low-cost
clinical test or biomarker for arthralgia is available for use
in regular clinical practice. In addition, the role of inflammation and other biomarkers in arthralgia remains unclear; past
efforts have been unsuccessful in validating patient-reported
arthritis pain instruments against erythrocyte sedimentation
rate, C-reactive protein, antinuclear antibodies, anti-doublestranded DNA, anticyclic citrullinated peptide, rheumatoid
factor, and uric acid.21,22 Therefore, the vast majority of
research and clinical practice must rely on patient reports
for assessment of arthralgia.
The Western Ontario and McMaster Universities Arthritis
Index7 and Joint-Specific Multidimensional Assessment of
Pain23 measure pain intensity and affect, but in only one joint
at a time (eg, knees). The Joint-Specific Multidimensional
Assessment of Pain includes ten items per joint queried.
These scales do not allow one to study arthralgia in multiple
joints simultaneously, yet arthralgia was observed to occur in
more than one joint location in the Breast Cancer Adjuvant
Therapy cohort study.5 Querying only one specific joint or
bilateral joint pair could miss potential statistically or clinically significant arthralgia in other areas of the body. The
Regional Pain Scale comes closer to measuring the construct
of pain throughout the body, but queries pain severity in
both nonarticular and articular regions. The Regional Pain
Scale has only four response options (none, mild, moderate,
or severe),24 while 11-point (0–10) numeric rating scales
have been demonstrated in past methodological research
to have a higher degree of sensitivity and validity for pain
assessment.25
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A reliable and valid measure of arthralgia severity is
needed to assemble consistent epidemiological outcomes
information about prevalence, incidence, time to onset, risk
factors, severity, and duration of arthralgia, as well as to better understand the role of arthralgia in the effectiveness of
AI treatment and the relationship between inflammation and
AI-associated arthralgia. Such a measure is also needed to
develop AI adherence interventions based on arthralgia management strategies; improving management of arthralgia has
been suggested as the key to promoting AI adherence.26
In order to address the need for a valid and reliable arthralgia severity measurement instrument, we developed the
Patient-Reported Arthralgia Inventory (PRAI) in the context
of a longitudinal cohort study of arthralgia, health-related
quality of life, and medication adherence. We adapted
the PRAI from the articular regions of the Regional Pain
Scale in collaboration with its author,24 revising the response
options to follow best practices in patient-reported outcome
measurement27 and pain measurement. The PRAI uses a
0–10 numeric rating scale to assess pain severity over a recall
period of the preceding 7 days. Our objectives were to evaluate the psychometric properties of the PRAI, assessing the
scale’s reliability and construct validity, and exploring how
duration of morning stiffness relates to arthralgia.

Materials and methods
Study design and setting
Survey data were collected in a longitudinal prospective
cohort study (ClinicalTrials.gov identifier NCT00954564),
with 52 weeks of follow-up per participant. Written informed
consent was obtained from each study participant. The study
was approved by the Vanderbilt University institutional review
board and consisted of self-administered paper questionnaires
completed at weeks 0, 2, 4, 6, 8, 12, and 52. Study personnel at Vanderbilt Ingram Cancer Center, Vanderbilt Institute
for Medicine and Public Health, and Vanderbilt Women’s
Health Research conducted the screening, enrollment, data
collection, and analysis. Data were managed using Research
Electronic Data Capture (REDCap).28

Participants
We recruited participants into three groups: women initiating AIs, women who had taken AIs but were no longer on
AI therapy, and postmenopausal women who had never been
diagnosed with breast cancer (comparison group). We chose
these three groups to serve the aims of our parent study’s program of research to understand the time course and duration of
treatment-emergent arthralgia with regard to AI initiation and
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cessation. Because arthralgia is common in postmenopausal
women irrespective of breast cancer diagnosis or endocrine
therapy (affecting 45%–55% of the population),1,2 the comparison group was selected to assess the background rate of
arthralgia in menopause, thus helping us quantify treatmentemergent arthralgia severity in the parent study. Participants
were recruited either by their treating physician at the Vanderbilt University Medical Center or via study advertisements in the greater Nashville area between 2009 and 2013.
Participants in all groups had to be female, postmenopausal
(self-report of at least 12 months without a menstrual period,
unrelated to surgery or medication), 35–90 years of age, and
have active self-reported performance status (3).29
Participants in the first group had to initiate anastrozole, exemestane, or letrozole within 30 days of baseline
assessment. Those in the second group had to have taken one
of these three medications in the past and since discontinued
for any reason. Comparison group participants had to
acknowledge never having been told by a physician that
they had breast cancer. Patients were ineligible if they were
undergoing treatment for any other (nonbreast) cancer, were
unable to provide informed consent, did not speak English,
were pregnant, or had metastatic disease. Screening was done
by telephone or via online self-administration. For the group
of women who had stopped taking AIs, only a baseline survey was administered. Follow-up for the longitudinal AI and
comparison groups was done by telephone and mail contact
to assist participants in staying on schedule. Women were
considered lost to follow-up if they had missed more than two
surveys in a row and could not be reached after six attempts.
Cohort screening and enrollment, as well as the derivation of
the final analytic sample, are shown in Figure 1.

Variables
We developed and administered the PRAI for the purpose
of measuring arthralgia severity in multiple joint locations.
The PRAI consists of 16 items that query pain severity over
the last 7 days in eight joint pair groups: bilateral (left and
right as two separate sets of items) fingers, wrists, elbows,
shoulders, hips, knees, ankles, and toes. The questionnaire
uses a rating scale of 0–10, with 10 being greatest severity
(Table S1). We scored the PRAI by first calculating the sum
of responses across all joints, ranging from 0 to 160. For
ease of interpretation, the average severity of pain per joint
(0–10) was then calculated by dividing the total score by the
number of items answered.
Data on several related constructs were collected concomitantly with the PRAI. Comorbidities were assessed using
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a checklist. For the analyses we categorized comorbidities
as joint-related (osteoarthritis, rheumatoid arthritis, psoriatic
arthritis, lupus, gout, ankylosing spondylitis, fibromyalgia,
osteoporosis, osteopenia, or Sjogren’s syndrome) or not
joint-related (diabetes, heart disease, hypertension, chronic
obstructive pulmonary disease, Parkinson’s disease, renal
failure, urinary tract problems, gastrointestinal problems,
anemia, eye problems, or no other comorbidity). We assessed
physical function and pain interference using the previously validated Patient-Reported Measurement Information
System (PROMIS) scales.30,31 PROMIS physical function
and pain interference scores were standardized according to
the PROMIS instructions. We measured performance status
using a patient-reported adaptation of the Eastern Cooperative Oncology Group (ECOG) performance status measure.32
The Functional Assessment of Cancer Therapy-Endocrine
Subscale (FACT-ES) was administered to measure menopausal symptom severity.33 The last item of the FACT-ES
instrument is “I have pain in my joints”, with the following
response options: “None,” “A little bit,” “Somewhat,” “Quite
a bit,” and “Very much.” This item about arthralgia was added
to the FACT-ES as a result of the findings regarding secondary effects of the AI anastrozole in the Arimidex, Tamoxifen
Alone or in Combination trial.34,35
As a patient-reported proxy for the presence of inflammation,36 we collected information regarding the duration
of morning stiffness in minutes. Respondents who answered
“yes” to the question “Over the past 7 days, have you had
overall morning stiffness in your muscles or joints?” were
asked how many minutes the morning stiffness had lasted. A
check box was available to indicate if the morning stiffness
had lasted more than 120 minutes. If a value for duration
was entered and the “more than 120 minutes” box checked,
we used the reported value.

Statistical methods
To assess the reliability of the PRAI, we calculated its internal
consistency via Cronbach’s alpha for the overall score and for
the score with each item removed. Additionally, we assessed
test-retest reliability in the comparison group, in which minimal change would be expected, by examining the change in
scores assessed at 2-week intervals (weeks 0 and 2, weeks 2
and 4, and so on). For each set of biweekly measurements,
we computed a Spearman correlation coefficient with a 95%
confidence interval (CI) to assess the strength of associations,
and generated Bland-Altman plots to evaluate agreement. We
also computed the intraclass correlation coefficient (ICC)
and corresponding CIs.
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– White, non-Hispanic (n=789, 42.4%)
– Black, non-Hispanic (n=80, 4.3%)
– Hispanic (n=21, 1.1%)
– Other (n=24, 1.3%)
– Missing/unknown/refused (n=953, 51.3%)

Excluded (n=1,064, 57.2%)
– Not prescribed AI in time window (n=979, 92%)
– Pre-menopausal, pregnant, or <35 years of age (n=56, 5.3%)
– Self ECOG (n=1, 0.1%)
– Current treatment for another cancer (n=3, 0.3%)
– Incomplete screening data (n=25, 1%)

Eligible (n=572, 30.8%)
– AI group (n=131, 22.9%)
– AI completers (n=81, 14.2%)
– Comparison group (n=360, 62.9%)

Not reached or declined (n=231, 40.4%)
– AI group (n=33, 14.3%)
– AI completers (n=45, 19.5%)
– Comparison group (n=153, 66.2%)

Consented and enrolled (n=341, 59.6%)
AI group (n=98, 28.7%)

AI completers (n=36, 10.6%)

– White, non-Hispanic (n=90, 91.8%)
– Black, non-Hispanic (n=3, 3.1%)
– Hispanic (n=1, 4.1%)
– Other (n=2, 2%)
– Missing/unknown (n=3, 3.1%)

– White, non-Hispanic (n=28, 77.8%)
– Black, non-Hispanic (n=7, 19.4%)
– Hispanic (n=0, 11.1%)
– Other (n=1, 2.8%)
– Missing/unknown (n=0, 0%)

– White, non-Hispanic (n=177, 85.5%)
– Black, non-Hispanic (n=21, 10.1%)
– Hispanic (n=3, 1.4%)
– Other (n=1, 0.5%)
– Missing/unknown (n=5, 2.4%)

Incomplete baseline data (n=11, 3.2%)
– AI group (n=4, 36.4%)
– AI completers (n=0, 0%)
– Comparison group (n=7, 63.6%)

Final analytic sample (n=330, 96.8%)
– AI group (n=94, 28.5%)
– AI completers (n=36, 10.9%)
– Comparison group (n=200, 60.6%)

Figure 1 Flow diagram of cohort screening and enrollment.
Abbreviations: AI, aromatase inhibitor; ECOG, Eastern Cooperative Oncology Group.

To examine the construct validity of the PRAI, we
assessed both known-groups validity and convergent validity.
Known-groups validity was addressed by: comparing PRAI
scores of AI patients with those of comparison group subjects at baseline and over time; and comparing PRAI scores
of patients with joint comorbidities with those without joint
comorbidities at baseline. Wilcoxon rank-sum tests and boxplots were used to assess differences in groups for each of the
above comparisons. We assessed concurrent validity by comparing PRAI scores at baseline and at follow-up with scores
from the single FACT-ES question reporting pain in joints.
To assess convergent validity, we examined whether PRAI
scores correlated with other validated measures, including the
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PROMIS physical function, PROMIS pain interference, and
ECOG performance status. Spearman correlation coefficients
and CIs were used to evaluate these associations.
To better understand the relationship between morning
stiffness and arthralgia, we examined the association of PRAI
scores with patient-reported duration of morning stiffness
using Spearman correlation coefficients, Bland-Altman plots,
and ICCs. CIs for Spearman correlation coefficients were
obtained using percentiles of bootstrap samples.

Results
Data from 330 women were included in the final analysis
(Figure 1). A detailed breakdown of population characteristics,
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Test statistic

95% CI

P-value

0, 2
2, 4

ICC

0.87
0.94

0.82–0.90
0.92–0.96

<0.0001
<0.0001

4, 6

0.94

0.91–0.95

<0.0001

6, 8
0, 2
2, 4

0.96
0.71
0.86

0.94–0.97
0.59–0.80
0.78–0.91

<0.0001
<0.0001
<0.0001

4, 6

0.85

0.77–0.91

<0.0001

6, 8

0.84

0.76–0.90

<0.0001

Spearman ρ

Abbreviations: CI, confidence interval ; PRAI, Patient-Reported Arthralgia Inventory;
ICC, intraclass coefficient.

univariate descriptive characteristics, and univariate comparisons by group can be found in Castel et al.5 The individual
PRAI items were all highly positively skewed; the median
value for all items was zero. Respondents reported the lowest
arthralgia severity in the elbows and higher arthralgia severity
in the knees, hips, and shoulders. Cronbach’s alpha for the
PRAI pain severity items was estimated to be 0.90. None of
the alpha values based on individual item removal were greater
than the total alpha, indicating that no item was negatively
affecting the scale’s internal consistency reliability.
Test-retest reliability is reported in the form of ICC
coefficients, which were calculated within subjects in
Weeks 0 and 2
3
2
1
0
−1
−2
−3
0

1

2

3

4

5

6

Difference between two pain
mean scores

Average of two pain mean scores

Weeks 4 and 6
3
2
1
0
−1
−2
−3
0

1

2

3

4

5

6

Average of two pain mean scores

Difference between two pain
mean scores

Test

the comparison group using PRAI assessments collected
2 weeks apart (Table 1). ICC values ranged from 0.87 to 0.96
for the repeated assessments. The corresponding Spearman
correlation coefficient estimates also indicate fairly strong
associations (range: 0.71–0.86). The Bland-Altman plots
in Figure 2 show levels of agreement between assessments
taken 2 weeks apart. There is strong overall agreement, with
less agreement between weeks 0 and 2 than at subsequent
time points.
With regard to validity, Figure 3 shows boxplots of
baseline PRAI scores for those participants with and without joint comorbidities. The estimated difference in mean
scores between groups was -0.3 (CI -0.5, -0.2; P0.001).
As expected, women with joint comorbidities tended to
have higher arthralgia severity scores than those without
joint comorbidities. The Wilcoxon rank-sum test of the null
hypothesis that both groups had the same distribution of
scores was highly significant (P0.001), suggesting knowngroups validity with respect to joint comorbidity.
Figure 4 shows boxplots of the PRAI scores in relation
to different levels of response to the FACT-ES item “I have
pain in my joints” separately by week. The PRAI scores
increase with higher FACT-ES ratings, further indicating
known-groups validity. Table 2 lists the Spearman correlation estimates between the two measures over time, which

Difference between two pain
mean scores

Weeks

Difference between two pain
mean scores
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Table 1 Estimated ICC and Spearman ρ for PRAI scores for one
patient taken 2 weeks apart

Weeks 2 and 4
3
2
1
0
−1
−2
−3
0

1

2

3

4

5

6

Average of two pain mean scores

Weeks 6 and 8
3
2
1
0
−1
−2
−3
0

1

2

3

4

5

6

Average of two pain mean scores

Figure 2 Test-retest reliability. Bland-Altman plot of agreement between Patient-Reported Arthralgia Inventory assessments taken 2 weeks apart, with smoothed curve.
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0.57–0.72; P0.001). ECOG performance status that was
not fully active was associated with higher PRAI scores
(estimated difference in location scores: -0.6, 95% CI
-0.9, -0.4; P0.001).
Figure 5 shows a plot of the duration of morning stiffness
in minutes and PRAI scores at baseline. The Spearman correlation between these measures was 0.62 (95% CI 0.54–0.69;
P0.0001), indicating greater morning stiffness among those
women with higher PRAI scores.

8

Mean pain score

4

2

Discussion
0
No joint comorbidity

Joint comorbidity

Figure 3 Baseline mean Patient-Reported Arthralgia Inventory scores by presence
of joint comorbidity.

show high associations (range: 0.76–0.82). This supports the
concurrent validity of the PRAI.
We assessed convergent validity by examining the relationship between the mean PRAI scores and each of the
PROMIS physical function T scores, PROMIS pain interference T scores, and ECOG performance status. PRAI scores
tended to be lower among those with better physical function
scores (estimated Spearman correlation coefficient: -0.47,
95% CI -0.55, -0.37; P0.001). PRAI scores were higher
among those with higher PROMIS pain interference
(estimated Spearman correlation coefficient: 0.65, 95% CI

8
6
4
2
0

None

Since the discovery of arthralgia as a secondary effect of AIs,
there has been a need for a validated multi-item arthralgia
measurement instrument. Our overall objective was to understand the psychometric properties of the PRAI. Our findings
can be interpreted in the context of established thresholds
for strength of association. For Cronbach’s alpha,37 a threshold value of 0.70 indicates good internal consistency;38 we
observed very high internal consistency reliability (0.90)
among the PRAI pain severity items. Similarly, 0.70 is a
criterion for adequate test-retest reliability.39 The PRAI’s
high ICC values (range: 0.87–0.96) indicate that the variation in scores at each 2-week interval is almost exclusively
due to differences between patients, rather than variability
within patients.
We observed that despite the PRAI’s strong overall
test-retest reliability, with all coefficients exceeding 0.70,
arthralgia severity was reported higher at baseline than at

Week 0

Week 2

Week 4

Week 6

Week 8

Week 12

Week 16

Week 52

8
6
4
2
0

Mean PRAI score
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6

Little
bit

Somewhat Quite Very much
a bit

None

Little
bit

8
6
4
2
0

8
6
4
2
0

Somewhat Quite Very much
a bit

Figure 4 Mean PRAI score by response to the FACT-ES item “I have pain in my joints” over time.
Abbreviations: PRAI, Patient-Reported Arthralgia Inventory; FACT-ES, Functional Assessment of Cancer Therapy-Endocrine Subscale.
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Weeks

Spearman

95% CI

P-value

0
2
4
6
8
12
16
52

0.82
0.80
0.76
0.80
0.82
0.82
0.81
0.79

0.78–0.87
0.74–0.85
0.69–0.83
0.75–0.85
0.77–0.87
0.76–0.86
0.73–0.87
0.72–0.85

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

Abbreviations: CI, confidence interval; FACT-ES, Functional Assessment of Cancer
Therapy-Endocrine Subscale; PRAI, Patient-Reported Arthralgia Inventory.

any subsequent assessment. This resulted in less agreement
between scores at weeks 0 and 2 than those at later weeks
among the women without breast cancer. Mishra and Kuh
similarly observed greater patient-reported menopausal
symptom severity upon first assessment as compared with
subsequent assessments in a general population, excluding the baseline data from their results for this reason.2 In
the absence of a feasible biological explanation for why
symptom severity might be greater at baseline than at later
assessments, future research should examine a potential
pattern of greater severity the first time a symptom severity
question is asked.
Our findings confirmed expectations based on past
research that greater arthralgia severity as reflected by higher
PRAI scores was associated with increased severity/impact
of other symptoms of post menopause, aging, and illness
in general as reflected by other patient-reported outcomes
measures. Specifically, we observed concomitant decline

6

Mean PRAI score
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Table 2 Estimated Spearman correlation between mean PRAI
score and FACT-ES item “I have pain in my joints” by week

in physical function, increased interference of pain with
activities of daily living, reduced performance status, and
increased morning stiffness among the patients with greater
PRAI-measured arthralgia severity. Our finding regarding
increased morning stiffness as a proxy for inflammation
suggests that patients experiencing more severe arthralgia
were more likely to present with patient-reported symptoms
of inflammation. Further research should explore, perhaps
by administering the PRAI concurrently with biomarker collection and/or rheumatology examination (including range
of motion assessment), the role of arthralgia in inflammation and vice versa, so that diagnostic methods, treatments,
and/or symptom-dependent decisions regarding AI therapy
may be more informatively developed for and discussed
with patients.
The PRAI fulfills an important clinical research need for
a multi-item scale, the benefits of which for measurement are
described by Nunnally and Bernstein.38 Because the PRAI was
developed in collaboration with patients and with experts in
rheumatology, it also has good face and content validity. Our
previous work with this scale also lends evidence to support
its construct validity. The model-based trajectory of PRAI
scores in women initiating AI therapy at baseline diverged at
week 6 from the trajectory of postmenopausal women without
cancer (P0.01). The trajectories also showed an increase in
arthralgia severity among those taking AI therapy over the
52 weeks of per-participant observation.5
Our findings indicate that this instrument has satisfactory
reliability and validity for use in assessing the severity of
arthralgia in clinical and nonclinical/general populations. Our
key results indicate strong internal consistency and test-retest
reliability of the PRAI, and provide evidence of its construct
validity using a multi-method approach.
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These questions are about pain in specific joints over the past 7 days. Please rate your pain in each joint using a number from 0 through 10, with 0
being no pain at all and 10 being the worst pain you can imagine
0
None
Left finger joints?
Right finger joints?
Left wrist joints?
Right wrist joints?
Left elbow joint?
Right elbow joint?
Left shoulder joint?
Right shoulder joint?
Left hip joint?
Right hip joint?
Left knee joint?
Right knee joint?
Left ankle joints?
Right ankle joints?
Left toe joints?
Right toe joints?

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

10
As bad as you
can imagine
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6

7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7

8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8

9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9

10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

Notes: Patient-Reported Arthralgia Inventory v2.0 ©Vanderbilt University. Dove Press and the authors request that persons interested in administering the PRAI in patient
populations for research or clinical purposes write to the authors at information@facit.org asking permission to use the PRAI for your study or clinical care. Please include
the following as briefly as possible: your scientific aims; your sample and recruitment methods; a list of your key collaborators; and your analysis plan. There is no charge to
use the PRAI, but written permission must be granted via email, based on the authors’ review of your plans for use of this copyrighted instrument.
Abbreviation: PRAI, Patient-Reported Arthralgia Inventory.
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